Skip to main content
Clinical Trials/NCT06366074
NCT06366074
Withdrawn
Not Applicable

Early-feasibility Study to Evaluate Usability and Safety of the Watch-Transcutaneous Electrical Acustimulation (TEA) Device

University of Michigan1 site in 1 country20 target enrollmentOctober 1, 2025
ConditionsHealthy

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Healthy
Sponsor
University of Michigan
Enrollment
20
Locations
1
Primary Endpoint
Usability of the device for both groups day 3
Status
Withdrawn
Last Updated
7 months ago

Overview

Brief Summary

This project is being completed to test the usability and safety of the Watch-Transcutaneous Electrical Acustimulation (TEA) Device.

This is a pilot study that will lead to future projects for cancer patients that may experience chemotherapy-induced symptoms.

Detailed Description

This project will include three different aims (aim three is a clinical trial) and will be funded by the National Institute of Health (NIH). In aims 1 and 2 the device hardware and device application will be developed and will not be included in this registration as these are not clinical trials. However, aim three is being registered early in the project in order to obtain the Notice of Award (NOA) funding from the NIH. Once the NOA has been obtained the registration will be updated.

Registry
clinicaltrials.gov
Start Date
October 1, 2025
End Date
October 1, 2026
Last Updated
7 months ago
Study Type
Interventional
Study Design
Crossover
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Jiande Chen

Professor of Internal Medicine

University of Michigan

Eligibility Criteria

Inclusion Criteria

  • Participants that are willing and able to come to the clinic for two scheduled visits
  • Participants are capable of understanding clinical study procedures
  • Participants agree to complete the questionnaires

Exclusion Criteria

  • Participants with implanted medical devices for electrical stimulation (e.g. cardiac pacemaker)
  • Those enrolled in a concurrent clinical study
  • Those unable to comply with the study protocol due to a disease, psychiatric illness, alcoholism, substance abuse, geographic distance, or other factors that would place the study participant at increased risk or preclude the study participant's full compliance with or completion of the study

Outcomes

Primary Outcomes

Usability of the device for both groups day 3

Time Frame: Day 3

Questionnaires are administered online and there are 17 usability questions in the questionnaire. All answers use 0-to-5 scale (0 - no,1 - minor, 2 - some, 3 - considerable, 4 - major, 5 - critical) with a range of 0-85 with a higher score meaning more usable.

Number of adverse events related to the device noted on the safety questionnaire

Time Frame: 1-2 weeks (after baseline visit 1)

A safety questionnaire with 3 questions about skin irritation, pain, or infection. Visit 2 is at 1-2 weeks after visit 1.

Number of Transcutaneous Electrical Acustimulation (TEA)-related adverse events for both groups 3 days

Time Frame: Day 3

These will include skin irritation, pain, or infection under the Watch-TEA and tethered TEA devices after wearing each device for 3 consecutive days. Adverse events will be noted by the following: 1. \- Mild averse event (AE) - No treatment needed 2. \- Moderate AE - Resolved with treatment 3. \- Severe AE - Inability to carry on normal activities, required professional medical attention 4. \- Life-threatening or disabling AE 5. \- Fatal AE

Number of TEA-related adverse events for both groups 60 minutes at maximal tolerable level

Time Frame: Daily for 3 days

The subjects will self-apply the TEA for 60 minutes once daily with the current amplitude set at a maximal tolerable level. Events collected will include skin irritation, pain, or infection. Adverse events will be noted by the following: 1. \- Mild AE - No treatment needed 2. \- Moderate AE - Resolved with treatment 3. \- Severe AE - Inability to carry on normal activities, required professional medical attention 4. \- Life-threatening or disabling AE 5. \- Fatal AE

Number of non-treatment TEA adverse events for both groups

Time Frame: up to 1-2 weeks (after baseline visit 1)

Adverse events will be noted by the following: 1. \- Mild AE - No treatment needed 2. \- Moderate AE - Resolved with treatment 3. \- Severe AE - Inability to carry on normal activities, required professional medical attention 4. \- Life-threatening or disabling AE 5. \- Fatal AE

Study Sites (1)

Loading locations...

Similar Trials